Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISORB: Vismodegib for Orbital and Periocular Basal Cell Carcinoma
NCT02436408Phase 4Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2015
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vismodegib in basal cell carcinoma (BCC), sponsored by University of Michigan Rogel Cancer Center. Started Jul 2015; status: completed.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02436408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436408.